Navigation Links
SALVAT has Completed Patient Enrollment in a Dose Finding Phase II Trial of SVT-40776 for the Treatment of Overactive Bladder
Date:10/9/2007

Results Expected to be Delivered by November 2007

BARCELONA, Spain, October 9 /PRNewswire/ -- This double-blind, placebo-controlled and multi-center Phase II trial includes 332 patients with Overactive Bladder (OAB) and has been conducted at 77 sites in 11 countries (US, Germany, Spain, The Netherlands, Czech Republic, Hungary, Poland, Russia, South Africa, New Zealand and Australia). The company expects to report the results of this trial during November.

The total study treatment duration after screening and baseline has been 4 weeks. Patients have been randomized into one of five treatment arms, which include one placebo, one active control (Tolterodine, 4 mg once daily) and three SVT-40776 groups (once daily administration). The primary endpoint of the trial is the mean change from baseline to last day of treatment in the number of micturitions per day. The trial will also generate tolerability data.

"The successful completion of patient enrollment in this clinical trial represents an important milestone in the development of SVT-40776" said Jordi Julve, CEO.

"We are very excited to look at the data regarding the efficacy and safety of SVT-40776 and to confirm the excellent profile suggested by our previous clinical data. We expect that SVT-40776 will improve the efficacy/tolerability ratio compared to the current available treatments, being the treatment of choice for patients with OAB" continued Mr. Julve.

About SVT-40776

SVT-40776 is a new potent and selective M3 muscarinic antagonist for the treatment of OAB with high bladder/salivary gland selectivity, long half life and low metabolic rate. Compared to oxybutynin, tolterodine, solifenacin and darifenacin, SVT-40776 is the most potent and selective M3 vs M2 yet developed. This profile is expected to give SVT-40776 an improved efficacy and tolerability, increasing the benefit/risk ratio.

About SALVAT

SALVAT is an independent, privately owned, Spanish pharmaceutical group closely identified with technological innovation and strongly committed to R&D. In 2006 SALVAT's products were distributed in more than 30 countries all over the world in collaboration with well reputed pharmaceutical partners. SALVAT is working to strengthen its international presence by licensing its own developments, e.g. CETRAXAL eardrops (currently under US-FDA review) and by emphasizing collaborations regarding its pipeline products.

Contact:

Cristina Viayna,

Business Development & Licensing

cviayna@salvatbiotech.com

http://www.salvatbiotech.com


'/>"/>
SOURCE SALVAT
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sensitive detection of tumor cells in peripheral blood of carcinoma patients by a reverse transcription PCR method
2. Quantitation of GAD67 Gene Expression in Prefrontal Cortex of Schizophrenia Patients Using the iCycler iQ Detection System and Molecular Beacons, Rev A
3. Milwaukee takes another step in electronic patient data exchange
4. What patients want: A story of choice, clinical trials & evidence-based medicine
5. GE partner allows real-time access to patient data
6. Sun, TeraMedica solution aimed at doctor-patient relationship
7. Interview: Dr. William Yasnoff on patient-centric IT
8. Video game technology could improve physician-patient interactions
9. GE and Intermountain want to streamline nationwide patient data
10. Human factors and IT: Designing for patient safety
11. The challenges of maintaining patient privacy and delivering secure clinical information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2017)... (PRWEB) , ... August 11, 2017 , ... ... food production, and, in particular, more natural alternatives to synthetic ingredients,” said Matt ... of Third Wave, with the established manufacturing presence and know-how of Biorigin will ...
(Date:8/10/2017)... ... August 09, 2017 , ... Teachers from ... students. From August 14th through the 16th, the University City Science Center will ... summer of 2016, provides Philadelphia-based middle school educators an opportunity for professional development ...
(Date:8/10/2017)... ... 09, 2017 , ... Each year in the United States more than 300,000 ... an independent lifestyle and, even worse, the one-year mortality rate is high, ranging from ... University of California Davis Medical Center (Sacramento) and Second Xiangya Hospital of the Central-South ...
(Date:8/10/2017)... California, USA (PRWEB) , ... August 09, 2017 ... ... has partnered with four international biomedical optics laboratories — the Wellman Center for ... Hospital, Medical Laser Center Lübeck and the Beckman Laser Institute at University of ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 30.37% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
Breaking Biology News(10 mins):